<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2940">
  <stage>Registered</stage>
  <submitdate>16/09/2010</submitdate>
  <approvaldate>16/09/2010</approvaldate>
  <nctid>NCT01215084</nctid>
  <trial_identification>
    <studytitle>A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers</studytitle>
    <scientifictitle>A Single-Dose, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>218HV101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BIIB041 (Fampridine-PR)

Experimental: Chinese Subpopulation: Fampridine-PR 10 mg - Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs

Experimental: Japanese Subpopulation: Fampridine-PR 10mg - Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs

Experimental: Caucasian Subpopulation: Fampridine-PR 10mg - Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs


Treatment: drugs: BIIB041 (Fampridine-PR)
A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of participants with treatment-emergent adverse events in each ethnic group</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Observed maximum (peak) plasma 4-aminopyridine (4-AP) concentration (Cmax)</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to reach Cmax following study treatment administration (Tmax)</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the time-concentration curve from time zero to infinity (AUC0-8)</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Apparent elimination half-life (T1/2)</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Renal clearance of the drug from plasma</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Renal clearance as a fraction of total clearance</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cumulative excreted drug amount at specified sampling intervals (calculated using the concentration data)</outcome>
      <timepoint>Day 1 (0 to 24 Hours After Dosing)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (PHI) in
             accordance with national and local subject privacy regulations.

          -  Subjects of Chinese or Japanese origin (at least both maternal and paternal
             grandparents of Chinese or Japanese origin, respectively), or Caucasian subjects.
             Japanese subjects should be on Japanese diet on a regular basis.

          -  All male subjects and female subjects of childbearing potential must practice
             effective contraception during the study and be willing and able to continue
             contraception for 4 weeks after their single dose of study treatment.

          -  Body Mass Index (BMI) within the range 18.5 to 30 kg/m2 (inclusive).

          -  Normal urinalysis results as determined by the Investigator for the following
             parameters: protein, glucose, specific gravity, ketones, urobilinogen, bilirubin, pH,
             and blood.

          -  Normal 12-lead ECG as determined by the Investigator.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Known history of human immunodeficiency virus (HIV) infection or positive test result
             for HIV antibodies.

          -  Known history of hepatitis B or hepatitis C infection, hepatitis B carrier (positive
             test result for Hepatitis B Surface Antigen [HBsAg]), or hepatitis C infection
             (positive test result for Hepatitis C virus antibody [HCV Ab]).

          -  Psychiatric or neurological disorders.

          -  History of epilepsy or other convulsive disorders.

          -  Any cardiovascular, renal, gastrointestinal, respiratory, metabolic disorder, or other
             major disease, as determined by the Investigator.

          -  Clinically significant abnormal hematology or blood chemistry values at Screening, as
             determined by the Investigator; or any screening values for alanine aminotransferase
             (ALT) and aspartate aminotransferase (AST) that are 1.5 times greater than the upper
             limit of the normal; any clinically significant (as determined by the Investigator)
             elevated screening values for bilirubin or creatinine; creatinine clearance lower than
             80 mL/minute; any low screening values for platelets or hemoglobin; or an out of
             normal range for white blood cells (WBC).

          -  History of alcohol abuse (as defined by the Investigator) within the previous 2 years,
             or a blood screen positive for alcohol.

          -  History of drug abuse (as defined by the Investigator) within the previous 2 years, or
             a urine screen positive for cannabinoids, barbiturates, amphetamines, and
             benzodiazepines.

          -  Premalignant and malignant disease.

          -  History of clinically significant severe allergic or anaphylactic reactions.

          -  Known allergy to pyridine-containing substances.

          -  Active bacterial or viral infection within the previous month.

          -  Female subjects who are pregnant or currently breastfeeding.

          -  Previous participation in another investigational drug study within the last 3 months.

          -  Treatment with any prescription medication within the 28 days prior to Day -1.
             (Treatment with pharmaceutical-grade vitamins is allowed provided the dose and regimen
             have been stable for the 28 days prior to Day -1.)

          -  Treatment with any over-the-counter products, including herbal-containing and/or
             caffeine-containing preparations, and/or alternative health preparations and
             procedures within the 2 days prior to Day -1.

          -  Donation of blood (500 mL or greater) within 56 days prior to study dosing or plasma
             donation within 7 days prior to study dosing.

          -  Inability to comply with study requirements.

          -  Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec,
             make the subject unsuitable for enrollment.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Acorda Therapeutics</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to determine the Pharmacokinetic (PK) and safety
      profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers. The
      secondary objective of this study is to compare the PK and safety profiles of fampridine-PR
      10 mg among the Chinese, Japanese, and Caucasian adult healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01215084</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>